Targacept signs antidepressant deal with AstraZeneca
This article was originally published in Scrip
Executive Summary
AstraZeneca and Targacept have signed a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD).